Subscribe
svetlana-lukienko-shutterstock-com
Svetlana Lukienko / Shutterstock.com
27 November 2015Asia-Pacific

Dr Reddy’s secures thrombosis drug rights in $17.5m deal

Indian pharmaceutical company Dr Reddy’s has agreed a deal to buy global intellectual property rights to a generic version of GSK’s deep vein thrombosis (DVT) treatment Arixtra (fondaparinux sodium) as part of a $17.5 million deal with a partner company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Dr. Reddy’s inks COVID-19 licensing deal amid furore over IP waiver
13 May 2021   India-based generics drug maker Dr. Reddy's Laboratories has entered into a voluntary licensing agreement with Eli Lilly to expand access to COVID-19 treatment in India.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Dr. Reddy’s inks COVID-19 licensing deal amid furore over IP waiver
13 May 2021   India-based generics drug maker Dr. Reddy's Laboratories has entered into a voluntary licensing agreement with Eli Lilly to expand access to COVID-19 treatment in India.

More on this story

Big Pharma
Dr. Reddy’s inks COVID-19 licensing deal amid furore over IP waiver
13 May 2021   India-based generics drug maker Dr. Reddy's Laboratories has entered into a voluntary licensing agreement with Eli Lilly to expand access to COVID-19 treatment in India.

More features

Takeda loses AMR treatment patent used in kidney transplants
Withers & Rogers hires cell and gene therapy expert
Medtech firm strikes out part of Apple button patent in ECG row
Tissue repair VP gets new trial over secrets damages
Labcorp's bid to invalidate Ravgen's DNA testing patent hits roadblock
Troutman Pepper Locke exodus sees teams leave in Chicago and London
Ex-Baker McKenzie patent litigation head joins Morgan Lewis in Germany
Mitsubishi Tanabe takes on Indian generic drugmaker’s ALS application